Score one for Samsung Bioepis in its quest to bring a biosimilar version of AbbVie’s anti-inflammatory behemoth Humira to market in Europe. This week, a U.K. court upturned two of the
Score one for Samsung Bioepis in its quest to bring a biosimilar version of AbbVie’s anti-inflammatory behemoth Humira to market in Europe. This week, a U.K. court upturned two of the